BiondVax Competitors

Delisted . USA . 
Stock . BiondVax Pharmaceuticals
BVXVDelisted Stock  USD 1.35  0.03  2.17%   
BiondVax Pharmaceuticals competes with Salarius Pharmaceuticals, SAB Biotherapeutics, Vaccinex, GeoVax Labs, and Molecular Partners; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing BiondVax Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of BiondVax Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of BiondVax Pharmaceuticals competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BiondVax Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
1.351.351.35
Details
Intrinsic
Valuation
LowRealHigh
1.281.281.49
Details

BiondVax Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between BiondVax Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of BiondVax and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of BiondVax Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
PEPG
+ 0.93
FWBI
PHVS
+ 0.65
MOLN
MLYS
+ 0.52
SLRX
PEPG
+ 0.46
MLYS
PHVS
+ 0.44
MLYS
MLYS
+ 0.43
FWBI
  
High negative correlations   
SABS
- 0.77
FWBI
PEPG
- 0.69
SABS
ANTX
- 0.62
FWBI
PEPG
- 0.54
ANTX
PEPG
- 0.53
GOVX
MLYS
- 0.41
GOVX

Risk-Adjusted Indicators

There is a big difference between BiondVax Stock performing well and BiondVax Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze BiondVax Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
FWBI  5.73 (1.84) 0.00 (1.29) 0.00 
 0.00 
 8.65 
(14.74)
 65.42 
SLRX  4.57  0.36  0.08  0.21  4.62 
(5.81)
 11.41 
(8.86)
 27.43 
SABS  6.46  1.00  0.14  1.36  6.60 
(7.65)
 19.02 
(11.25)
 65.66 
VCNX  7.70 (0.76) 0.00 (0.22) 0.00 
 0.00 
 12.36 
(24.82)
 85.55 
GOVX  5.41  0.30  0.05 (0.20) 5.29 
(7.72)
 12.63 
(8.97)
 77.95 
MOLN  4.18  0.42  0.08 (1.10) 4.14 
(5.93)
 9.38 
(6.35)
 52.92 
MLYS  2.90  0.20  0.04 (0.34) 3.55 
(3.00)
 7.51 
(5.79)
 20.98 
ANTX  2.82  0.51  0.17  0.68  2.27 
(4.76)
 8.94 
(4.72)
 28.89 
PHVS  2.82  0.12  0.03 (1.04) 3.71 
(3.23)
 6.79 
(6.64)
 23.21 
PEPG  4.17 (1.04) 0.00 (1.65) 0.00 
 0.00 
 6.70 
(9.30)
 29.46 
All Fundamental Data

BiondVax Pharmaceuticals Competitive Analysis

The better you understand BiondVax Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, BiondVax Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across BiondVax Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
BVXV FWBI SLRX SABS VCNX GOVX MOLN MLYS ANTX PHVS
 2.17 
 1.35 
BiondVax
 4.69 
 0.61 
First
 0.60 
 1.67 
Salarius
 1.95 
 4.18 
SAB
 1.82 
 1.12 
Vaccinex
 4.68 
 2.46 
GeoVax
 0.19 
 5.30 
Molecular
 0.39 
 12.82 
Mineralys
 1.47 
 1.38 
AN2
 0.36 
 19.43 
Pharvaris
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Dangerous
Dangerous
Extremely Dangerous
Dangerous
Unstable
Not too volatile
Moderately volatile
Not too volatile
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Modest
OK
Very Weak
Weak
Insignificant
Weak
OK
Insignificant
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Dangerous
High
About Average
Average
Very High
Low
Low
Average
Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Hold
Strong Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Hold
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Strong Sell
Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Buy
Strong Sell
Current Ratio
1.71
0.1
8.31
1.72
8.22
9.51
14.37
N/A
28.17
12.85
Net Asset
27.07 M
6.88 M
6.59 M
83.94 M
3.63 M
9.28 M
198.35 M
251.64 M
138.74 M
398.69 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(10.5 M)
(15.74 M)
(2.84 K)
(38.08 M)
(19.75 M)
(26.67 M)
(59.53 M)
(84.66 M)
4.9 M
(96.85 M)
Current Valuation
21.94 M
72.56 M
(557.82 K)
11.96 M
1.62 M
21.79 M
27.75 M
643.61 M
(54.01 M)
740.24 M
Price To Book
7.48
1.87
0.82
1.03
7.34
2.73
1.27
2.7
0.47
3.43
Operating Margin
N/A
N/A
N/A
-34.23
N/A
-16.84
-21.42
N/A
N/A
N/A
Retained Earnings
(115.83 M)
(184.33 M)
(76.35 M)
(90.06 M)
(339.93 M)
(104.36 M)
(191.75 M)
(124.71 M)
(154.46 M)
(265.92 M)
Current Asset
36.93 M
N/A
N/A
N/A
N/A
1.24 M
N/A
N/A
N/A
N/A
Beta
2.37
1.28
0.93
0.64
0.99
3.11
0.54
N/A
-0.22
-3.14
Number Of Employees
33
9
2
57
37
17
167
28
41
83
Shares Outstanding
3.65 M
2.03 M
1.44 M
9.23 M
2.68 M
9.44 M
36.86 M
49.77 M
29.88 M
54.23 M
Cash Flow From Operations
(7.26 M)
(12.38 M)
(12.85 M)
(25.12 M)
(17.23 M)
(25.17 M)
(59.01 M)
(81.17 M)
(53.29 M)
(93.05 M)
Total Debt
21.54 M
826.84 K
289.64 K
5.91 M
247 K
3.52 M
3.65 M
10.48 M
14.04 M
238.91 K
Return On Equity
-56.02
-0.15
-1.2
-1.75
-7.59
-3.62
-0.37
-0.61
-0.69
-0.45
Z Score
-6.6
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.31
-0.27
-0.54
-0.79
-4.96
-1.34
-0.21
-0.39
-0.43
-0.27
Number Of Shares Shorted
4.88 K
46.6 K
26.34 K
56.42 K
62.11 K
511.22 K
48.79 K
1.59 M
74.08 K
152.06 K
Book Value Per Share
-1.96
7.99
10.74
4.0
-2.59
2.92
4.18
4.76
4.19
7.35
Current Liabilities
1.7 M
N/A
1.97 M
N/A
N/A
126.99 K
N/A
N/A
N/A
N/A
Total Asset
27.07 M
6.88 M
6.59 M
83.94 M
3.63 M
9.28 M
198.35 M
251.64 M
138.74 M
398.69 M
Short Ratio
0.32
1.02
0.08
1.22
0.6
0.35
4.49
5.73
0.82
1.49
Target Price
39.0
36.0
26.0
12.4
7.0
14.6
10.35
32.57
2.67
34.25
Debt To Equity
N/A
0.077
0.003
0.16
0.024
0.009
0.02
N/A
N/A
0.001
Shares Owned By Institutions
10.69
1.46
0.36
34.24
51.3
10.82
5.31
97.39
52.31
87.5
Market Capitalization
4.97 M
5.99 M
2.4 M
38.58 M
2.86 M
23.21 M
195.74 M
640.52 M
41.23 M
1.06 B
Price To Earning
-4.91
N/A
N/A
N/A
N/A
-1.25
1.85
N/A
3.96
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.12
Price To Sales
N/A
N/A
18.12
25.5
4.38
77.2
32.61
N/A
N/A
N/A
Net Income
(5.8 M)
(15.79 M)
(12.54 M)
(42.19 M)
(20.25 M)
(25.97 M)
(61.98 M)
(71.9 M)
(64.73 M)
(99.83 M)
Earnings Per Share
-2.35
-47.88
-5.14
-6.3
7.42
-8.39
-2.09
-3.31
-1.99
-2.7
Shares Owned By Insiders
20.01
5.66
2.52
19.15
11.5
0.52
N/A
2.61
21.63
9.49
Revenue
N/A
N/A
N/A
2.24 M
570 K
N/A
7.04 M
N/A
N/A
N/A
Working Capital
12.03 M
1.82 M
5.22 M
48.09 M
(2.57 M)
4.37 M
178.04 M
238.62 M
96.46 M
383.25 M
Cash And Equivalents
14.55 M
1.16 M
22.65 M
16.62 M
11.4 M
30.9 M
267.13 M
N/A
113.39 M
201.38 M
Cash Per Share
2.23
0.83
10.09
0.39
0.27
1.25
8.22
N/A
5.84
5.96
Gross Profit
N/A
N/A
(15.84 M)
(12.53 M)
(13.7 M)
81.53 K
138.85 M
N/A
N/A
N/A
Day Typical Price
1.36
0.62
1.65
4.24
1.12
2.45
5.29
12.92
1.38
19.22
Accumulation Distribution
0.0429
0.11
1766.34
0.0788
10.73
78037.75
9.91
10982.93
0.0496
804.44
Market Facilitation Index
0.06
0.07
0.0
0.35
0.0
N/A
0.0
0.0
0.07
0.0
Daily Balance Of Power
(0.50)
(0.43)
0.1111
0.2286
2.0
0.6111
(0.50)
(0.05)
0.2857
(0.09)
Period Momentum Indicator
(0.03)
(0.03)
0.01
0.08
0.02
0.11
(0.01)
(0.05)
0.02
(0.07)
Rate Of Daily Change
0.98
0.95
1.01
1.02
1.02
1.05
1.0
1.0
1.01
1.0
Day Median Price
1.37
0.63
1.65
4.27
1.13
2.44
5.29
12.97
1.38
19.11
Price Action Indicator
(0.04)
(0.03)
0.03
(0.04)
0.005
0.075
0.005
(0.17)
0.015
0.29
Coefficient Of Variation
(570.46)
(466.36)
1432.47
964.2
(1,810)
3521.78
1643.75
2060.26
910.72
3033.32
Mean Deviation
2.62
5.73
4.57
6.46
7.7
5.41
4.18
2.9
2.82
2.82
Jensen Alpha
(0.64)
(1.84)
0.3649
1.0
(0.76)
0.2979
0.4171
0.1982
0.5107
0.1238
Total Risk Alpha
(0.74)
(2.04)
0.2408
0.744
(1.03)
(0)
0.2172
0.0736
0.3915
0.0104
Sortino Ratio
N/A
N/A
0.0755
0.141
N/A
0.0452
0.0829
0.0436
0.1679
0.0255
Downside Variance
N/A
N/A
26.01
50.13
N/A
29.77
21.74
14.11
9.07
15.12
Standard Deviation
3.6
8.39
5.98
9.94
12.22
9.81
6.89
4.04
4.9
3.98
Kurtosis
1.39
5.87
0.503
7.85
9.09
22.71
15.0
1.39
10.76
1.8
Potential Upside
5.04
8.65
11.41
19.02
12.36
12.63
9.38
7.51
8.94
6.79
Treynor Ratio
4.95
(1.29)
0.2141
1.36
(0.22)
(0.20)
(1.10)
(0.34)
0.6833
(1.04)
Maximum Drawdown
17.48
65.42
27.43
65.66
85.55
77.95
52.92
20.98
28.89
23.21
Variance
12.98
70.44
35.7
98.76
149.43
96.29
47.42
16.33
24.0
15.85
Market Risk Adjusted Performance
4.96
(1.28)
0.2241
1.37
(0.21)
(0.19)
(1.09)
(0.33)
0.6933
(1.03)
Risk Adjusted Performance
(0.13)
(0.16)
0.0643
0.0919
(0.03)
0.0318
0.0573
0.0467
0.0959
0.0343
Skewness
0.2366
0.3647
0.7097
1.97
(2.21)
3.93
2.79
0.5115
2.87
(0.34)
Semi Deviation
N/A
N/A
4.62
6.6
N/A
5.29
4.14
3.55
2.27
3.71
Information Ratio
(0.18)
(0.22)
0.0644
0.1005
(0.06)
0.0251
0.0562
0.0406
0.1032
0.0249
Value At Risk
(6.54)
(14.74)
(8.86)
(11.25)
(24.82)
(8.97)
(6.35)
(5.79)
(4.72)
(6.64)
Expected Short fall
N/A
N/A
(5.81)
(7.65)
N/A
(7.72)
(5.93)
(3.00)
(4.76)
(3.23)
Downside Deviation
N/A
N/A
5.1
7.08
N/A
5.46
4.66
3.76
3.01
3.89
Semi Variance
N/A
N/A
21.36
43.54
N/A
28.03
17.18
12.63
5.15
13.76

BiondVax Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of BiondVax Pharmaceuticals Competition

BiondVax Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by BiondVax Pharmaceuticals in relation to its competition. BiondVax Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of BiondVax Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact BiondVax Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to BiondVax Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your BiondVax Pharmaceuticals position

In addition to having BiondVax Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Driverless Cars Thematic Idea Now

Driverless Cars
Driverless Cars Theme
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Consideration for investing in BiondVax Stock

If you are still planning to invest in BiondVax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BiondVax Pharmaceuticals' history and understand the potential risks before investing.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY